Wild swings in Biolidics' shares after news of Covid-19 test kit deal
Singapore
SHARES of Biolidics rapidly lost the bulk of their gains accumulated from recent days, after the medtech firm announced that Nasdaq-listed Aytu Bioscience will be the exclusive distributor of its Covid-19 rapid test kit in the United States.
The frenzied trading kicked off at 3.30pm on Thursday once Biolidics' trading halt was lifted, and proceeded to set off the Singapore Exchange's (SGX) circuit breaker at least once in the final hour of trading.
KEYWORDS IN THIS ARTICLE
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Companies & Markets
Singapore stocks end lower even as regional markets rally; STI slips 0.1%
New Thai finance minister downplays row with central bank
South-east Asia increasingly used for illicit money flows, terrorist financing: US Treasury official
Apac finance M&A to stay subdued after Q1 decline as uncertainties linger: S&P Global
Japan's Nikkei closes at 3-week high on US rate-cut outlook, tech boost
Philippines’ PLDT in talks to sell up to 49% of data centre business to Japan’s NTT